Xeris Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$10.1M
Doctors Paid
30,905
Transactions
98,367
2024 Total
$1.7M
Payment Breakdown by Category
Research$6.3M (62.0%)
Food & Beverage$2.0M (19.8%)
Consulting$488,621 (4.8%)
Travel$148,228 (1.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.3M | 263 | 62.0% |
| Food and Beverage | $2.0M | 95,817 | 19.8% |
| Honoraria | $848,286 | 460 | 8.4% |
| Consulting Fee | $488,621 | 247 | 4.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $228,056 | 122 | 2.3% |
| Travel and Lodging | $148,228 | 627 | 1.5% |
| Education | $103,193 | 829 | 1.0% |
| Grant | $17,000 | 2 | 0.2% |
Payments by Type
Research
$6.3M
263 transactions
General
$3.8M
98,104 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| XP-8121-108 | $3.1M | 0 | 20 |
| XP-8121-120 | $1.3M | 0 | 58 |
| XP-9164-109 | $711,566 | 0 | 7 |
| COR-2017-OLE | $312,787 | 1 | 88 |
| GLUCAGON INFUSION IN T1D PATIENTS WITH RECURRENT SEVERE HYPOGLYCEMIA: EFFECTS ON COUNTER-REGULATORY RESPONSES | $253,965 | 0 | 7 |
| A PHASE 1, OPEN-LABEL, SINGLE-ARM, THREE-TREATMENT, THREE-WAY, CROSSOVER PHARMACOKINETICS STUDY OF XP-0863 IN HEALTHY SUBJECTS | $224,374 | 0 | 1 |
| A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL FOLLOWING OPEN LABEL THERAPY STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEVOKETOCONAZOLE (2S, 4R-KETOCONAZOLE) IN THE TREATMENT OF ENDOGENOUS CUSHING'S SYNDROME | $140,066 | 0 | 29 |
| PHASE 2, RANDOMIZED, OPEN-LABEL, CROSSOVER, PD/PK STUDY OF A NOVEL PRAM-INSULIN CO-FORMULATION IN ADULTS WITH T1D | $75,427 | 0 | 10 |
| AN OPEN-LABEL EXTENSION STUDY OF LEVOKETOCONAZOLE (2S,4R-KETOCONAZOLE) IN THE TREATMENT OF ENDOGENOUS CUSHING'S SYNDROME | $70,251 | 0 | 24 |
| HEED the Glucagon Access Program (HEED the GAP) | $53,000 | 0 | 1 |
| GLUCAGON READY TO USE (RTU) IN SUBJECTS WITH HYPERINSULINEMIC HYPOGLYCEMIA AFTER BARIATRIC SURGERY | $42,766 | 0 | 11 |
| COR-2017-01 | $9,429 | 0 | 7 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Frank D'alessandro, M.d, M.D | Endocrinology, Diabetes & Metabolism | North Providence, RI | $17,378 | $0 |
| Unknown Provider | — | — | $16,449 | $0 |
| Maria Fleseriu, Md, MD | Endocrinology, Diabetes & Metabolism | Portland, OR | $16,371 | $0 |
| Jennifer Dyer, Md, MD | Pediatric Endocrinology | Columbus, OH | $16,143 | $0 |
| Dr. David Domek, Md, MD | Specialist | Oklahoma City, OK | $14,754 | $0 |
| Dr. Wendy Lane, Md, MD | Endocrinology, Diabetes & Metabolism | Asheville, NC | $14,503 | $0 |
| Mrs. Ashlyn Smith, Pa-C, PA-C | Medical | Chandler, AZ | $14,167 | $0 |
| Richard Auchus, Md, MD | Endocrinology, Diabetes & Metabolism | Ann Arbor, MI | $13,674 | $0 |
| Dr. Rachel Bier, M.d, M.D | Endocrinology, Diabetes & Metabolism | Englewood, NJ | $12,386 | $0 |
| Dr. Kevin Yuen, Mbchb, Md, Frcp(Uk), MBCHB, MD, FRCP(UK) | Endocrinology, Diabetes & Metabolism | Phoenix, AZ | $12,227 | $0 |
| Oksana Hamidi, D.o, D.O | Endocrinology, Diabetes & Metabolism | Dallas, TX | $11,714 | $0 |
| Alison Gracom, Pa, PA | Medical | Irvine, CA | $11,597 | $0 |
| Thomas Brefeld, Md, MD | Hospitalist | Rockford, IL | $10,891 | $0 |
| Anthony Pick, M.d, M.D | Endocrinology, Diabetes & Metabolism | Deerfield, IL | $10,298 | $0 |
| Wahid Kassar, M.d, M.D | Endocrinology, Diabetes & Metabolism | Chicago, IL | $10,094 | $0 |
| Unknown Provider | — | — | $9,591 | $0 |
| Dr. Vinay Kapoor, M.d, M.D | Internal Medicine | Bayside, NY | $9,134 | $0 |
| Amer Kassar, Md, MD | Endocrinology, Diabetes & Metabolism | Dekalb, IL | $9,025 | $0 |
| Dr. Martin Sarkar, D.o, D.O | Endocrinology, Diabetes & Metabolism | Frederick, MD | $8,720 | $0 |
| Minou Tran, M.d, M.D | Endocrinology, Diabetes & Metabolism | Pico Rivera, CA | $8,671 | $0 |
| Lowell Schmeltz, Md, MD | Endocrinology, Diabetes & Metabolism | Farmington Hills, MI | $8,660 | $0 |
| Yuvraj Kumbkarni, M.d, M.D | Endocrinology, Diabetes & Metabolism | Tampa, FL | $8,646 | $0 |
| Mrs. Amy Butts, Pa-C, PA-C | Physician Assistant | Wellsburg, WV | $8,570 | $0 |
| Steve Fordan, Md, MD | Endocrinology, Diabetes & Metabolism | Dallas, TX | $8,538 | $0 |
| Eliza Geer, Md, MD | Endocrinology, Diabetes & Metabolism | New York, NY | $8,300 | $0 |
Ad
Top Products
- GVOKE PFS $1.9M
- GVOKE HYPOPEN $1.5M
Associated Products (3)
- GVOKE PFS $1.9M
- GVOKE HYPOPEN $1.5M
- RECORLEV $892,493
Payment Categories
- Food & Beverage $2.0M
- Consulting $488,621
- Travel & Lodging $148,228
- Research $6.3M
About Xeris Pharmaceuticals, Inc.
Xeris Pharmaceuticals, Inc. has made $10.1M in payments to 30,905 healthcare providers, recorded across 98,367 transactions in the CMS Open Payments database. In 2024, the company paid $1.7M. The top product by payment volume is GVOKE PFS ($1.9M).
Payments were distributed across 224 medical specialties. The top specialty by payment amount is Endocrinology, Diabetes & Metabolism ($1.2M to 2,308 doctors).
Payment categories include: Food & Beverage ($2.0M), Consulting ($488,621), Research ($6.3M), Travel & Lodging ($148,228).
Xeris Pharmaceuticals, Inc. is associated with 3 products in the CMS Open Payments database.